Nexstim Oy, a medical device manufacturer based in Finland, received CE Mark approval from the European Union for its Navigated Brain Therapy (NBT) system. The NBT system is a non-systemic, non-invasive therapeutic device that provides customized treatment for major depression. The device also received CE Mark approval as an adjunct therapy for patients recovering from strokes. The NBT’s navigation features give healthcare providers the ability to quickly and accurately target cortical structures that are involved in neurological health disorders.
Brain stimulation therapy has been used for the treatment of depression for over a decade. In brain stimulation therapy, a patient wears a specialized apparatus next to his or her head. This device delivers pulsed magnetic fields that stimulate part of the cerebral cortex. This targeted region of the cerebral cortex is believed to be responsible for mood control.
The NBT System by Nexstim offers several significant advantages over other similar products on the market. Nexstim uses MRI-based navigation technologies that give healthcare providers the ability to visualize the electric field found inside a patient’s brain. This eliminates the “hit or miss” issues found in other non-targeted systems. In addition, this system gives healthcare providers the ability to replicate procedures across a variety of different patients. The NBT system is designed to be used as part of an outpatient procedure. It has none of the side effects associated with pharmacological interventions or invasive treatment techniques.